Joele Frank, Wilkinson Brimmer Katcher works the Chapter 11 filing of Dendreon Corp., the Seattle-based biopharmaceutical house and maker of cancer treatment Provenge.
Approved by the Food and Drug Administration in 2010, Provenge was touted as a promising treatment for prostate cancer.
The high average cost of $93K for a drug that improved survival rate for just over months prevented its widespread support by doctors.
Dendreon's recapitalization could lead to its acquisition of sale of key assets.
CEO Thomas Amick expressed confidence that the restructuring "will allow Provenge to remain commercially available to patients and providers who have come to rely on this revolutionary personalized cancer immunotherapy.
JFWBK's Andy Brimmer and Aaron Palash handle Dendreon.
Teneo is handling the initial public offering of CVC Capital Partners, one of Europe’s largest private equity firms with nearly $200B in assets under management.
Brunswick Group represents Endeavor Group Holdings as it agrees to go private via its acquisition by Silver Lake technology investment firm, which is handled by Edelman Smithfield.
Tod Donhauser, a nine-year veteran of Edelman, has joined H/Advisors Abernathy as managing director and head of its San Francisco office.
Intelligent Group Ltd, a Hong Kong-based financial PR firm, has priced its initial public offering of 1.9M shares at $4, which is the low end of the $4 to $5 range.
Kekst CNC represents Grant Thornton as it sells a majority stake in its US arm to New Mountain Capital, which relies on Goldin Solutions, in what is billed as the largest PE investment in the accounting and advisory sector.
Have a comment? Send it to 
No comments have been submitted for this story yet.